Undervalued Drug Manufacturer Stocks on NAS March 2024

March 16, 2024

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
GRFS Grifols 6.13 12.47 103.53 3555984 4164 0.00 62.1
LNTH Lantheus Holdings 58.15 95.37 64.01 987112 4084 0.00 12.5
EVO Evotec 6.89 10.14 47.11 59753 2438 0.00 0.0
GILD Gilead Sciences 73.71 83.47 13.24 7237193 92727 4.10 16.4
AZN AstraZeneca 66.31 71.91 8.45 5602875 207152 2.19 34.8
NBIX Neurocrine Biosciences 139.17 147.29 5.83 874222 14056 0.00 56.3
AMPH Amphastar Pharma 43.05 43.85 1.85 554945 2282 0.00 16.6
HCM HUTCHMED (China) 17.62 17.79 0.95 127208 3063 0.00 29.4
SNY Sanofi 48.27 48.29 0.03 1487513 121293 3.94 20.5
All data provided as at market close March 14, 2024.

Company Details

Grifols

GRFS:NAS

Close Price

6.13

Our Valuation

12.47

% Difference

103.53

Market Cap ($M)

4164

P/E Ratio

62.1

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Access the stockcalc valuation


Lantheus Holdings

LNTH:NAS

Close Price

58.15

Our Valuation

95.37

% Difference

64.01

Market Cap ($M)

4084

P/E Ratio

12.5

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer.

Access the stockcalc valuation


Evotec

EVO:NAS

Close Price

6.89

Our Valuation

10.14

% Difference

47.11

Market Cap ($M)

2438

P/E Ratio

0.0

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Access the stockcalc valuation


Gilead Sciences

GILD:NAS

Close Price

73.71

Our Valuation

83.47

% Difference

13.24

Market Cap ($M)

92727

P/E Ratio

16.4

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

AstraZeneca

AZN:NAS

Close Price

66.31

Our Valuation

71.91

% Difference

8.45

Market Cap ($M)

207152

P/E Ratio

34.8

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Access the stockcalc valuation


Neurocrine Biosciences

NBIX:NAS

Close Price

139.17

Our Valuation

147.29

% Difference

5.83

Market Cap ($M)

14056

P/E Ratio

56.3

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Access the stockcalc valuation


Amphastar Pharma

AMPH:NAS

Close Price

43.05

Our Valuation

43.85

% Difference

1.85

Market Cap ($M)

2282

P/E Ratio

16.6

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers.

Access the stockcalc valuation


HUTCHMED (China)

HCM:NAS

Close Price

17.62

Our Valuation

17.79

% Difference

0.95

Market Cap ($M)

3063

P/E Ratio

29.4

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Access the stockcalc valuation


Sanofi

SNY:NAS

Close Price

48.27

Our Valuation

48.29

% Difference

0.03

Market Cap ($M)

121293

P/E Ratio

20.5

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Grifols and Lantheus Holdings are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-march-2024
Grifols $GRFS and Lantheus Holdings $LNTH are the most undervalued Drug Manufacturers stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-march-2024
Grifols and Lantheus Holdings are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-march-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.